Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salsalate in Type 1 Diabetes Neuropathy (TINSAL-T1DN)
NCT02936843Phase 3Completed
- Sponsor
- University of Michigan
- Start
- Oct 2016
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic neuropathy and Cardiovascular autonomic neuropathy (CAN) comparing Salsalate Arm with Placebo Arm (2 arms). Primary endpoint: Intraepidermal Nerve Fiber Density - Distal Thigh at 12 months. Started Oct 2016; status: completed.
02
Drugs
Amigesic
03
Conditions
diabetic neuropathyCardiovascular autonomic neuropathy (CAN)
Beyond the preview
Go deeper on NCT02936843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02936843.